Turning Point Therapeutics, Inc. Forms 3, 4 and 5: Preferred Stock
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 20 rows, 20 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2019-04-22: Reporting owner GLAXOSMITHKLINE PLC; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
- 2019-04-22: Reporting owner GLAXOSMITHKLINE PLC; Form 4; Security Series D Preferred Stock; Transaction C Conversion of derivative security.
- 2019-04-22: Reporting owner ORBIMED ADVISORS LLC | OrbiMed Capital GP VI LLC; Form 4; Security Series C Preferred Stock; Transaction C Conversion of derivative security.
- 2019-04-22: Reporting owner ORBIMED ADVISORS LLC | OrbiMed Capital GP VI LLC; Form 4; Security Series D Preferred Stock; Transaction C Conversion of derivative security.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2019-04-22 | GLAXOSMITHKLINE PLC Director, 10% Owner | 4 | Series C Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −4,314,809 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | GLAXOSMITHKLINE PLC Director, 10% Owner | 4 | Series D Preferred Stock Derivative · Indirect · See Footnote | C Conversion of derivative security | −2,105,259 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | ORBIMED ADVISORS LLC | OrbiMed Capital GP VI LLC Director | Director | 4 | Series C Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −4,314,809 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | ORBIMED ADVISORS LLC | OrbiMed Capital GP VI LLC Director | Director | 4 | Series D Preferred Stock Derivative · Indirect · See footnote | C Conversion of derivative security | −2,105,259 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | Lu Hongbo Director | 4 | Series C Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −4,314,809 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | Lu Hongbo Director | 4 | Series D Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −2,105,259 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | GORDON CARL L Director | 4 | Series C Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −4,314,809 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | GORDON CARL L Director | 4 | Series D Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −2,105,259 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | George Simeon Director | 4 | Series C Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −4,314,809 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-22 | George Simeon Director | 4 | Series D Preferred Stock Derivative · Indirect · (m) | C Conversion of derivative security | −2,105,259 0 owned after | $0.00 | 2019-04-24 | |
| 2019-04-16 holding as of filing | GLAXOSMITHKLINE PLC Director, 10% Owner | 3 | Series C Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | GLAXOSMITHKLINE PLC Director, 10% Owner | 3 | Series D Preferred Stock Derivative · Indirect · See Footnote | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | OrbiMed Capital GP VI LLC | ORBIMED ADVISORS LLC Director | Director | 3 | Series C Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | OrbiMed Capital GP VI LLC | ORBIMED ADVISORS LLC Director | Director | 3 | Series D Preferred Stock Derivative · Indirect · See footnote | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | Lu Hongbo Director | 3 | Series C Preferred Stock Derivative · Indirect · By LAV Prime Limited | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | Lu Hongbo Director | 3 | Series D Preferred Stock Derivative · Indirect · By LAV Prime Limited | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | GORDON CARL L Director | 3 | Series C Preferred Stock Derivative · Indirect · By OrbiMed Private Investments VI, LP | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | GORDON CARL L Director | 3 | Series D Preferred Stock Derivative · Indirect · By OrbiMed Private Investments VI, LP | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | George Simeon Director | 3 | Series C Preferred Stock Derivative · Indirect · By S.R. One, Limited | Holding | no price filed | 2019-04-16 | ||
| 2019-04-16 holding as of filing | George Simeon Director | 3 | Series D Preferred Stock Derivative · Indirect · By S.R. One, Limited | Holding | no price filed | 2019-04-16 |